In parallel, we believe that antibodies combined with small-molecule drugs might provide a promising direction for drug repositioning and other cancer treatment against drug resistance, and anti-ENO1 antibody combined with MET might serve as a potential precursor platform for screening ADC. Here, MET is linked to cancer.